Comera Life - CMRA STOCK NEWS

Comera Life Sciences Holdings, Inc. (CMRA) announced participation in four upcoming scientific and industry conferences, highlighting its innovative SQore™ formulation platform. The company aims to improve patient access and convenience for biologic medicines by developing subcutaneous (SQ) options.

Key events include:

• Excipient World Conference: May 1-3, 2023, in National Harbor, MD, featuring a presentation by Yuhong Zeng, Ph.D.
• Pharma Partnering Summit: May 4-5, 2023, in San Diego, CA, with 1x1 meetings.
• PEGS Boston Conference: May 15-19, 2023, in Boston, MA, with an exhibit booth.
• BIO International Convention: June 5-8, 2023, in Boston, MA, offering 1x1 meetings with key executives.

Comera's mission focuses on transforming IV therapies to SQ delivery for enhanced patient autonomy.

HDAX Therapeutics has appointed Dr. Roman Fleck as Executive Chairman and Dr. Neal I. Muni as an independent Board member, enhancing the leadership team's strategic capabilities. Dr. Fleck brings extensive experience from roles at Janpix, Inc. and Medicxi Ventures, while Dr. Muni has over 20 years in the biopharmaceutical sector and is currently the COO of Comera Life Sciences (NASDAQ:CMRA). Both are expected to advance HDAX's development of first-in-class therapies targeting neurological and cardiac diseases linked to microtubule dysfunction, which have significant unmet needs. Their appointments come at a critical juncture for HDAX, as the company aims to leverage its innovative platform technology for potential breakthroughs in treatment.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) has expanded its patent portfolio with a new patent granted in South Korea and Notices of Allowance in the U.S. and Japan for its SQore™ platform. These patents focus on excipients designed to lower the viscosity of biologics, particularly monoclonal antibodies, enhancing their subcutaneous delivery. The U.S. Notice of Allowance encompasses processing improvements using 1,3-dimethyluracil, while the South Korean patent covers hordenine, tryptamine, and trigonelline as viscosity-reducing agents. This expansion is expected to increase commercial market potential and lifecycle opportunities for Comera's products.

Comera Life Sciences Holdings, Inc. (CMRA) has expanded its collaboration with Regeneron, focusing on the development of a subcutaneous formulation of vedolizumab, enhancing patient access and convenience in treating inflammatory bowel disease. In Q4 2022, Comera reported revenues of $156,000, up from $73,000 in Q4 2021, primarily from research activities. However, net losses increased to $3.1 million for Q4 2022, compared to $2.0 million in Q4 2021, attributed to growing operational costs. For the full year 2022, revenues reached $633,000, with a net loss of $18.4 million. The company aims to leverage its innovations to shift biologic delivery from intravenous to subcutaneous forms, potentially reducing healthcare costs.

Comera Life Sciences Holdings, Inc. (CMRA) announced its participation in the 22^nd Annual PepTalk Conference, scheduled for January 18, 2023, at 5:15 p.m. PT in San Diego. Senior Research Scientist Subhashchandra Naik will present findings on viscosity reduction and stabilization with the SQore™ platform, which aids in developing highly concentrated monoclonal antibody formulations for subcutaneous use. This innovative technology aims to enhance patient care by allowing self-administration of biologic medicines.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) announced its upcoming presentation at the Biotech Showcase Conference on January 10, 2023, at 9:00 AM PT in San Francisco, CA. The event will also feature one-on-one investor meetings from January 9 to 11. Attendees can view the live presentation and access recorded sessions on-demand. Comera focuses on transforming biologic medicines from intravenous to subcutaneous delivery, aiming for better patient autonomy and convenience. More information is available on their Investor Relations website.

Comera Life Sciences Holdings (Nasdaq: CMRA) has successfully completed a private placement of 2,406,242 units at $1.48 each, generating approximately $3.6 million in gross proceeds. The units consist of one share of common stock and a five-year warrant to purchase two additional shares at $1.23 each. The funds will be used for working capital and corporate purposes. The private placement was backed by key existing investors and is not registered under the Securities Act, limiting resale options.

Comera Life Sciences Holdings, Inc. (CMRA) announced its participation in the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference on December 1, 2022, at the New York Athletic Club. The company focuses on developing innovative biologic medicines aimed at enhancing patient access and self-administration. Comera's approach seeks to transform intravenous treatments into subcutaneous forms, allowing patients greater independence in their care. Interested parties can access the investor presentation on their official site for more details.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) reported Q3 2022 financial results, showing revenues of $235,000, up from $88,000 in Q3 2021, primarily due to increased research activities. R&D expenses rose to $395,000, and general administrative expenses increased significantly to $2.3 million. The company experienced a net loss of $3.2 million, or $0.20 per share, compared to a net loss of $914,000, or $6.34 per share, year-over-year. Comera expanded its collaboration with Regeneron and introduced CLS-001, a subcutaneous formulation of vedolizumab, enhancing its treatment offerings for inflammatory bowel disease.